Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34707586

about

Osteonecrosis in children with acute lymphoblastic leukemia Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy How I treat acute lymphoblastic leukemia in older adolescents and young adults Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment Glucocorticoid-induced osteonecrosis.Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.Impairments that influence physical function among survivors of childhood cancer Effect of premedications in a murine model of asparaginase hypersensitivity Evidence for age as a modifier of genetic associations for lipid levels.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors Challenging issues in pediatric oncology Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells.Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.Inherited genetic variation in childhood acute lymphoblastic leukemia.Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia Pharmacogenomics of adverse effects of anti-leukemic agents in children.Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia Widespread osteonecrosis in children with leukemia revealed by whole-body MRI.Osteonecrosis in children after therapy for malignancy.Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Substrain-specific differences in survival and osteonecrosis incidence in a mouse model.Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).Milestones in the curability of pediatric cancers Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis.The adolescent and young adult with cancer: state of the art-- acute leukemias.Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232

P2860

Q28066799-B50F30B4-D922-466F-ABEF-222DF2A37CD3 Q28083449-C6EC4A8F-0B48-4C5A-9CAE-B207F8CB0CFF Q28087589-42642E45-C395-4B3B-9208-5051E3B66490 Q33557148-623D0C33-875B-4950-9A24-E18B49F78001 Q34026481-37AD2E8F-E976-40FC-B9A4-63F8A6A2893B Q34038283-5AC8DC22-43B6-455F-A54F-CA0F2B94262E Q34240713-106A9071-1A84-4958-8159-C5738060845A Q34267235-0C4E7687-5815-4C0B-97D3-64C557E5E559 Q34448969-0413E538-B283-49D7-95CB-CB0D1A943826 Q35006917-31AF79A0-D7D3-46C8-B6A9-4C30B08B0107 Q35065477-D587C400-177C-43FE-A204-1954AB78FA47 Q35082766-61AC068F-5A25-4AA8-A0BD-E4B92B84704E Q35156439-092BD9CD-8C31-4CA0-9C09-DC08D855E348 Q35162899-F8E55FA6-A0EA-4390-879B-4DFFB42A5E53 Q35327266-C46A2E15-A185-41DD-8D5D-0BE6C2888BB5 Q35602419-8723CFD1-59E3-4754-BDF4-7695FB4BA1D3 Q35667279-1EC05830-FCBB-4077-BD6D-CCDFD010DB4F Q35726310-3A499940-5CD3-44EE-B619-40A7E37A95B0 Q35740019-74D1D0AD-7F48-41A8-B65E-8ABDB27884D6 Q35776973-B099E0CE-D2C1-4BE4-BE7F-533EC8A2D07E Q35784497-B5AF680D-54C4-465A-9AE1-1E15AC6E26F3 Q35815806-5498B347-E04C-45CA-ABE6-193CFBCD1F60 Q35954058-59473538-5FE7-4D42-8DA0-9D16A06FD837 Q36064796-C2C68E6D-C464-4DBE-A1BB-E0959C310644 Q36143232-3F906CEF-1CF1-45CD-9668-D687A03947C8 Q36191097-FFAB4316-1862-4F73-8FCB-58BD1C154AF9 Q36251056-8962440D-F2C9-457B-A2C7-C820F1E91A3E Q36337592-6E3D4087-95B8-4008-896A-69CDEC6B7231 Q36381725-C62FC627-2B1C-43A6-81DB-CB176B50CEF7 Q36429353-2C119FC2-6BBA-454B-A4E1-391C6EE5A632 Q36452241-16606936-F8CE-4EDB-A837-AE848A9C694B Q36481285-5B9772A8-C179-4803-826D-6F2229BE43DF Q36547791-BC9E8A69-788E-41FC-AC19-FA0B5B9F9FD8 Q36678136-F267CAF8-74BC-45E1-95D7-ACF0D4E24A60 Q36895136-4EDB9D66-CEA8-47C2-ACB3-55EE278FE461 Q36925083-7DDB3832-DFCA-4F90-BCDF-03B31FDDFF7B Q36967138-26FE1FA2-9D77-4462-B50D-F294A730B47C Q36986496-D8BBFACD-DEC5-4CD5-AFA2-1FAFE4245A8E Q37134753-400FA69E-304E-48FF-8288-68C5A81BD467 Q37169331-6AF17DE8-59D9-44B8-B5CB-347A04190A3D

P2860

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34707586

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@ast

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@en

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@nl

type

label

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@ast

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@en

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@nl

prefLabel

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@ast

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@en

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@nl

P1433

Q34707586-FCCE669D-6CF1-489B-B319-CBDEF21626B9

P1476

Q34707586-7747D0A9-DB89-40EA-8AA4-6539BDC5EDA2

P2093

Q34707586-3833E641-2700-4620-B17B-2F1C0886ECE0

Q34707586-4B949AC1-0AB6-4F29-B99C-DCC631389AEE

Q34707586-67671894-05E2-48DF-AAD8-310E7DC73251

Q34707586-6E3C4A44-F984-4BCC-B743-381612AD4D62

Q34707586-8A9619A8-6ED8-4CD2-9A23-6A89174CBAEE

Q34707586-9A6F9E69-00BB-41C1-B11C-E903AA201373

Q34707586-B8B2EF14-5F54-43FB-A404-B03F244AD0AD

Q34707586-C3FEF05A-C84F-4631-9B74-27A525783FB3

Q34707586-EF05AF5B-BC5B-4C08-BBF7-A7ED42F0ED16

Q34707586-FFF62C5C-05E5-407B-962D-09CF588C6603

P2860

Q34707586-014B7496-7569-4AD8-969C-4973B8A6BC12

Q34707586-0BAE8289-A71F-4B88-9AB0-5921929C427F

Q34707586-0C8B71CD-3300-4FBF-9F5C-6EED946E6006

Q34707586-108D96D0-4028-4745-9681-50E44E0C8E01

Q34707586-22036975-0D86-4A52-A19A-6F959C002D1C

Q34707586-25174068-1A2F-49C9-84F8-7C163676C253

Q34707586-38971AB0-7726-47A6-9113-E168E9AC4581

Q34707586-418427B2-4C49-4560-BA9B-246ACFB7BB86

Q34707586-480D6D90-A850-415C-BFB1-E17D88512C20

Q34707586-571FE41B-3693-4E71-BDFA-54D682C9771A

P304

Q34707586-E75B0DF5-6C42-472F-9FA0-4E7089D7A07F

P31

Q34707586-B996FC6D-E6BD-424B-8FC5-AEF543852A14

P356

Q34707586-95D93408-BCAF-4022-B9AB-B992075355DB

P407

Q34707586-1BAE4ED5-D227-4071-902A-6706877F4DAB

P433

Q34707586-3C41DFF9-5E6D-427F-93C3-97D99FEE549E

P478

Q34707586-9470B5E5-C5C5-4F63-91FC-A419B94097DB

P50

Q34707586-9D5DE023-AEA9-4D3D-9D97-F38A4DCED444

P577

Q34707586-41B9E600-B45E-427C-8057-EDC8D4698A73

P5875

Q34707586-DAC63251-5FDA-4890-967F-5C090AAD4990

P698

Q34707586-D0CB1E78-418A-47CE-BDA2-3E7203B32019

P921

Q34707586-8A5A6622-1FC1-49DB-981A-FB779382E6F9

P932

Q34707586-692BB9B6-7C30-4BE7-A508-E6232664C8C3

P356

BLOOD-2010-10-311969

P1433

P1476

Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.

@en

P2093

Cheng Cheng

http://www.w3.org/2001/XMLSchema#string

Deqing Pei

http://www.w3.org/2001/XMLSchema#string

Geoffrey Neale

http://www.w3.org/2001/XMLSchema#string

Jitesh D Kawedia

http://www.w3.org/2001/XMLSchema#string

John C Panetta

http://www.w3.org/2001/XMLSchema#string

Mary V Relling

http://www.w3.org/2001/XMLSchema#string

Scott C Howard

http://www.w3.org/2001/XMLSchema#string

Sue C Kaste

http://www.w3.org/2001/XMLSchema#string

William E Evans

http://www.w3.org/2001/XMLSchema#string

Xiangjun Cai

http://www.w3.org/2001/XMLSchema#string

P2860

Inference of population structure using multilocus genotype data

Treating childhood acute lymphoblastic leukemia without cranial irradiation

A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

Statistical significance threshold criteria for analysis of microarray gene expression data.

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits.

Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.

High-throughput SNP genotyping on universal bead arrays.

P304

2340-7; quiz 2556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-10-311969

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49674666

http://www.w3.org/2001/XMLSchema#string

P698

21148812

http://www.w3.org/2001/XMLSchema#string

P921

P932

3062406

http://www.w3.org/2001/XMLSchema#string